Amneal Focuses On Complex Generics As Revenues See Double-Digit Growth
Company Also Plans To File 30 ANDAs This Year
After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business.
You may also be interested in...
Amneal is adding to its portfolio of complex products with FDA approval for a generic version of Lidoderm.
Around 80 more jobs are to go at Lannett, as the company reels from rival Amneal bagging US Food and Drug Administration approval for the company’s top seller.
Following approval by the FDA, Amneal has launched a generic version of the Butrans buprenorphine transdermal system, immediately initiating commercialization activities across all strengths.